T-Cell Lymphoma Clinical Trials

A listing of T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 70 clinical trials
Tislelizumab Combined With Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma

combination treatment in patients with relapsed or refractory Extranodal Natural Killer/T Cell Lymphoma(NKTCL)

  • 0 views
  • 04 Oct, 2022
  • 3 locations
  • 0 views
  • 24 Oct, 2022
  • 1 views
  • 17 Oct, 2022
  • 7 locations
BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20)

iRECIST can be applied for efficacy assessment) and subjects with cutaneous T-cell lymphoma (CTCL), specifically Sézary Syndrome (SS) and mycosis fungoides (MF). The study will consist of 2 phases

  • 38 views
  • 07 Oct, 2022
  • 5 locations
An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients With Lymphoid Malignancies (WWRD Study)

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

  • 7 views
  • 24 Oct, 2022
  • 7 locations
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side

adult t-cell leukemia/lymphoma
leukemia
measurable disease
anaplastic large cell lymphoma
angioimmunoblastic t-cell lymphoma
  • 0 views
  • 07 Oct, 2022
  • 40 locations
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment. Phase 1 part: Around 20~40 patients will be subsequently enrolled into 2

t-cell lymphoma
measurable disease
peripheral t-cell lymphoma
systemic therapy
  • 6 views
  • 07 Oct, 2022
  • 44 locations
A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma

This is a modular dose confirmation and expansion study. The core study design is to assess the efficacy of AZD4573, administered as monotherapy or combination therapy, to participants with either r/r PTCL or r/r cHL and to confirm the safety profiles and PK in these populations. Module 1 of this …

  • 0 views
  • 21 Oct, 2022
  • 11 locations
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

measurable disease
stem cell transplantation
  • 0 views
  • 04 Oct, 2022
  • 48 locations
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

leukemia
marginal zone lymphoma
waldenstrom's macroglobulinemia
follicular lymphoma
chronic lymphocytic leukemia
  • 0 views
  • 24 Oct, 2022
  • 21 locations